The Low Von Willebrand Factor in Ireland Cohort Study - Defining Optimal Management for Procedures in Patients with Low VWF (30-50 IU/dL)

Conclusion:This study represents the largest analysis of procedural outcomes in patients with Low VWF to date. Our data suggest that age and ISTH BAT score significantly influence choice of hemostatic prophylaxis. Bleeding complications were observed only in LoVIC patients undergoing DE covered by TA, or with minor procedures with no hemostatic cover. Interestingly, patients who developed bleeding were typically older (median 59.7y) and, critically in this subgroup, bleeding occurred despite that plasma VWF levels had corrected to within the normal range, clearly raising the possibility that age-corrected normal ranges may need to be considered.TableDisclosuresLavin: Shire: Honoraria, Research Funding, Speakers Bureau. O'Donnell: Bayer: Research Funding, Speakers Bureau; Baxter: Research Funding, Speakers Bureau; Shire: Research Funding, Speakers Bureau; Novo Nordisk: Research Funding, Speakers Bureau; Leo Pharma: Speakers Bureau; Octapharma: Speakers Bureau; CSL Behring: Consultancy; Daiichi Sankyo: Consultancy; Pfizer: Consultancy, Research Funding.

Source: Blood - November 21, 2018 Category: Hematology Authors: Doherty, D., Patel, A., Nolan, M., Byrne, M., Aguila, S., O'Sullivan, J. M., Ryan, K., O'Connell, N. M., Lavin, M., O'Donnell, J. S. Tags: 322. Disorders of Coagulation or Fibrinolysis: Poster I Source Type: research